Abivax (ABVX) Enterprise Value (2021 - 2026)

Abivax's Enterprise Value history runs 6 years deep, the most recent figure standing at -$584.7 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 266.32% year-over-year to -$584.7 million; the TTM figure through Mar 2026 stood at -$584.7 million (down 266.32% YoY), while the FY2025 annual figure was -$626.4 million, down 286.26% from the prior year.
• Enterprise Value was -$584.7 million for Q1 2026 at Abivax, up from -$626.4 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$27.5 million in Q4 2022 to a low of -$626.4 million in Q4 2025.
• Historically, Enterprise Value has averaged -$275.3 million across 5 years, with a median of -$273.7 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Enterprise Value soared 60.4% in 2022, then plunged 921.83% in 2023.
• A 5-year view of Enterprise Value shows it stood at -$27.5 million in 2022, then slumped by 921.83% to -$281.0 million in 2023, then jumped by 42.28% to -$162.2 million in 2024, then plunged by 286.26% to -$626.4 million in 2025, then rose by 6.65% to -$584.7 million in 2026.
• The last three Enterprise Value figures came in at -$584.7 million (Q1 2026), -$626.4 million (Q4 2025), and -$179.3 million (Q3 2025), per Business Quant data.